Analysis of the Efficacy and Safety of Intratymapanic Dexamethasone for Treating Meniere’s Disease: A Randomized Controlled Trial

Objectives Our objective was to study the efficacy and safety of intratymapanic dexamethasone (ITD) for treating in Méniere’s disease in southern China. Methods A total of 124 patients with Méniere’s disease were randomly divided into 2 groups: ITD group (n = 62) and intratympanic lidocaine (ITL) group (n = 62). The ITD group was further randomly divided into 2 groups based on dexamethasone dosage: ITD1 (2 mg/ml) (n = 31) and ITD2 (5 mg/ml) group (n = 31). Symptom alleviation and complications were recorded after every treatment. Results Vertigo was improved in 65% of patients who received ITD compared with 55% of patients who received ITL patients ( P < .05). Three patients in the ITD2 group had from otomycosis, and 2 of these patients had a perforation; no tympanic membrane perforation was observed in the ITL and ITD1 group. Conclusions Compared with lidocaine, dexamethasone is more effective in alleviating vertigo, and a lower concentration of dexamethasone can reduce the occurrence of complications.